Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
62.13
+0.91 (+1.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Halozyme Therapeutic
< Previous
1
2
3
4
5
6
7
Next >
NASDAQ:HALO is not too expensive for the growth it is showing.
April 23, 2024
NASDAQ:HALO stands out as a growth opportunity that won't break the bank.
Via
Chartmill
9 Analysts Have This To Say About Halozyme Therapeutics
April 16, 2024
Via
Benzinga
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
April 16, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Via
Chartmill
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
April 09, 2024
Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.
Via
Benzinga
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
April 05, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
Via
Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
April 02, 2024
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
Via
Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
February 21, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock and is consolidating.
Via
Chartmill
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
February 21, 2024
Via
Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
March 29, 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2.
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Via
Investor's Business Daily
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
March 14, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
March 13, 2024
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.
Via
InvestorPlace
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
March 11, 2024
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable.
Via
Chartmill
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
March 01, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals.
Via
Chartmill
Halozyme Therapeutics: Q4 Earnings Insights
February 20, 2024
Via
Benzinga
Earnings Preview: Halozyme Therapeutics
February 19, 2024
Via
Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
February 19, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) stands out as a growth opportunity that won't break the bank.
Via
Chartmill
Earnings Scheduled For February 20, 2024
February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.
Via
Benzinga
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
February 15, 2024
Michael Shpigelmacher, Founder and CEO of Bionaut Labs, with the company’s micro-robot designed to swim through the central nervous system into the brain to treat disease now on trial in the U.S.
Via
Benzinga
NASDAQ:HALO, an undervalued stock with good fundamentals.
February 09, 2024
Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued.
Via
Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
January 31, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
January 29, 2024
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.
Via
Benzinga
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
January 29, 2024
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
Via
Chartmill
NASDAQ:HALO: good value for what you're paying.
January 19, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals.
Via
Chartmill
Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts
January 18, 2024
Via
Benzinga
3 Biotech Stocks to Sell in January Before They Crash and Burn
January 25, 2024
The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell.
Via
InvestorPlace
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
January 18, 2024
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights.
Via
Benzinga
Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe
January 16, 2024
Roche's Tecentriq SC, the EU's first subcutaneous PD-(L)1 immunotherapy, approved for faster, 7-minute injections
Via
Benzinga
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
January 16, 2024
Healthcare stocks have underperformed in 2023, but that is expected to change this year.
Via
The Motley Fool
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
January 10, 2024
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.